

Disclosure Information J.S. Kemming: None. A. Kongsgaard: None. N.P. Kristensen: None. S.K. Saini: E. Ownership Interest (stock, stock options, patent or other intellectual property); Modest; Tetramer Shop. S.R. Hadrup: E. Ownership Interest (stock, stock options, patent or other intellectual property); Modest; Tetramer Shop, PokeACell, Immumap.

P09.21 **MODELLING THE SPATIAL DYNAMICS OF ONCOLYTIC VIROTHERAPY IN THE PRESENCE OF VIRUS-RESISTANT TUMOR CELLS**

¹DK Bhatt*, ²T Janzen, ¹T Daemen, ²FJ Weissing. ¹University medical center Groningen, Groningen, Netherlands; ²Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, Netherlands

10.1136/jitc-2022-ITOC9.77

Background Oncolytic virotherapy is a promising form of cancer treatment that uses native or genetically engineered viruses to target, infect and kill cancer cells. Unfortunately, this form of therapy is not effective in a substantial proportion of cancer patients, partly due to the occurrence of infection-resistant tumor cells.

Materials and Methods To shed new light on the mechanisms underlying therapeutic failure and to discover strategies that improve therapeutic efficacy we designed a cell-based model of viral infection. The model allows to investigate the dynamics of infection-sensitive and infection-resistant cells in tumor tissue in presence of the virus. To reflect the importance of the spatial configuration of the tumor on the efficacy of virotherapy, we compare three variants of the model: two 2D models of a monolayer of tumor cells and a 3D model. In all model variants, we systematically investigate how the therapeutic outcome is affected by properties of the virus (e.g. the rate of viral spread), the tumor (e.g. production rate of resistant cells, cost of resistance), the healthy stromal cells (e.g. degree of resistance to virus) and the timing of treatment.

Results We find that various therapeutic outcomes are possible when resistant cancer cells arise at low frequency in the tumor. These outcomes depend in an intricate but predictable way on the death rate of infected cells, where faster death leads to rapid virus clearance and cancer persistence. Our simulations reveal three different causes of therapy failure: rapid clearance of the virus, rapid selection of resistant cancer cells, and a low rate of viral spread due to the presence of infection-resistant healthy cells. Our models suggest that improved therapeutic efficacy can be achieved by sensitizing healthy stromal cells to infection, although this remedy has to be weighed against the toxicity induced in the healthy tissue.

Conclusions Through a modelling approach, our study provides insight into the dynamics of oncolytic virotherapy and resistance within a spatial framework. We demonstrate that the outcome of virotherapy depends not only on the parameters governing virus replication and the spatial architecture of the tumor but also on the presence of resistant-cancer and -stromal cells that act as a barrier to the spread of oncolytic virus. We hope that our computational approach aids in defining the impact of the various factors that may influence resistance and therapeutic efficacy of virotherapy. We are confident that our results, along with experimental observations, can assist the scientific community in improving the design of virotherapy.

Weblink to the preprint and the model: (<https://www.biorxiv.org/content/10.1101/2022.04.06.487254v1>)

Disclosure Information D.K. Bhatt: None. T. Janzen: None. T. Daemen: None. F.J. Weissing: None.

P09.22 **TOWARD A RATIONAL DESIGN OF IMMUNONANOTHERAPIES**

^{1,2,3,4,5}V Mittelheisser*, ⁶X Coubez, ^{1,3,4,5}O Lefebvre, ^{1,3,7,5}JG Goetz, ²A Detappe. ¹Tumor Biomechanics, INSERM UMR_S1109, CRBS, Strasbourg, France; ²Institut de Cancérologie Strasbourg-Europe, Strasbourg, France; ³Université de Strasbourg, Strasbourg, France; ⁴Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; ⁵Équipe Labellisée Ligue Contre le Cancer, Paris, France; ⁶CERN, Geneva, Switzerland; ⁷Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France

10.1136/jitc-2022-ITOC9.78

Cancer nanomedicine primarily aim to direct drugs delivery to cancer cells but tumoraccumulation remains suboptimal (Mittelheisser et al. Adv. Mater., 2022). To circumvent this limitation, activating immune cells with nanoparticles (NPs) is an emerging concept. However, upon engagement, whether NPs change the fate of immune cells that take them up remains unknown and one needs to thoroughly assess such impact to identify optimal NPs. Here, we characterized the response of immune cells to a selection of nanomaterials classically used in biomedical applications. Doing so, we aim at rationalizing the selection of specific NPs to undergo novel targeted approaches. Through bulk RNA-sequencing and proteomic analyses, we first investigated the impact of 6 NPs (lipidic, polymeric, organic/inorganic) on negatively isolated CD3 - CD56 + human NK cells and CD3 + human panT cells. Amongst all the NPs studied, we observed that the oxidated carbon nanotube triggered wide transcriptome and proteome modifications in both pan-T and NK cells, whereas the other NPs exhibit mild to low impact into both NK and pan T-cells. Interestingly, we observed that only polymeric NPs induced a pre-activated state in NK cells with an overexpression of the CCL5 chemokine and the cathepsin Z. Based on these results, we identified one type of polymeric NPs as potential candidate for further NK cell targeting approaches.

Disclosure Information V. Mittelheisser: None. X. Coubez: None. O. Lefebvre: None. J.G. Goetz: None. A. Detappe: None.

P09.23 **IMMUNE CELL INFILTRATION AS A NOVEL MARKER FOR PREDICTING PATIENT OUTCOME IN NEPHROBLASTOMA**

¹L Watzke*, ¹H Sorger, ¹F Palmisani, ¹M Metzelder, ²G Amann, ³M Bergmann. ¹Department of Pediatric Surgery, Medical University of Vienna, Vienna, Austria; ²Department of Pathology, Medical University of Vienna, Vienna, Austria; ³Department of General Surgery, Medical University of Vienna, Vienna, Austria

10.1136/jitc-2022-ITOC9.79

Background Gaining insights into the tumor microenvironment (TME) of adult cancers improved clinical outcome and enabled newlines of therapies for these patients. In pediatric cancers, which are known to have less extensive immune infiltrates, little is known about the TME. In nephroblastoma, with a 5-year survival rate of 80–90%, investigating the TME may hold the key to further improve patient prognosis and risk stratification.

Materials and Methods In a retrospective study including 110 patients with renal tumors treated according to the